Whether Denosumab is affecting central tolerance or affecting cells in the local microenvironment of tumors is unclear at the moment, and further investigation is needed to delineate how RANK/RANKL signal inhibition contributes to enhanced anti-tumor immunity. Here, TNFRSF11A is linked to neoplasm.